JP2019537605A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537605A5 JP2019537605A5 JP2019523859A JP2019523859A JP2019537605A5 JP 2019537605 A5 JP2019537605 A5 JP 2019537605A5 JP 2019523859 A JP2019523859 A JP 2019523859A JP 2019523859 A JP2019523859 A JP 2019523859A JP 2019537605 A5 JP2019537605 A5 JP 2019537605A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- naphthylidine
- propanoic acid
- azetidine
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, hydroxyl Chemical group 0.000 claims 252
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 208
- 235000019260 propionic acid Nutrition 0.000 claims 175
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 148
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 97
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 47
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 44
- 125000000217 alkyl group Chemical group 0.000 claims 38
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 32
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 27
- JJQXZWAHTLVGHM-UHFFFAOYSA-N 2-cyclobutylacetamide Chemical compound NC(=O)CC1CCC1 JJQXZWAHTLVGHM-UHFFFAOYSA-N 0.000 claims 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 17
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000004452 carbocyclyl group Chemical group 0.000 claims 14
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- DEOUZFWSQWEPGE-UHFFFAOYSA-N 2-methylheptanamide Chemical compound CCCCCC(C)C(N)=O DEOUZFWSQWEPGE-UHFFFAOYSA-N 0.000 claims 12
- 206010016654 Fibrosis Diseases 0.000 claims 12
- 230000004761 fibrosis Effects 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 125000004103 aminoalkyl group Chemical group 0.000 claims 10
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 10
- 229940124530 sulfonamide Drugs 0.000 claims 10
- 150000003456 sulfonamides Chemical class 0.000 claims 10
- JELHGGHSSHUANV-UHFFFAOYSA-N 2-(azetidin-3-yl)acetamide Chemical compound NC(=O)CC1CNC1 JELHGGHSSHUANV-UHFFFAOYSA-N 0.000 claims 9
- ATKQVWLLXIQODC-UHFFFAOYSA-N carbamic acid cyclobutane Chemical compound NC(=O)O.C1CCC1 ATKQVWLLXIQODC-UHFFFAOYSA-N 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 8
- 150000001408 amides Chemical class 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 8
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 7
- ZGVUUFZPJYGKFZ-UHFFFAOYSA-N 2-(azetidin-1-yl)acetamide Chemical compound NC(=O)CN1CCC1 ZGVUUFZPJYGKFZ-UHFFFAOYSA-N 0.000 claims 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 6
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 5
- VALZSZJVEFACEZ-UHFFFAOYSA-N azetidine-3-carboxamide Chemical compound NC(=O)C1CNC1 VALZSZJVEFACEZ-UHFFFAOYSA-N 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 4
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 206010023421 Kidney fibrosis Diseases 0.000 claims 3
- 230000001476 alcoholic effect Effects 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 231100000283 hepatitis Toxicity 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 1
- IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 239000001273 butane Substances 0.000 claims 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 1
- 125000004976 cyclobutylene group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- DROIHSMGGKKIJT-UHFFFAOYSA-N propane-1-sulfonamide Chemical compound CCCS(N)(=O)=O DROIHSMGGKKIJT-UHFFFAOYSA-N 0.000 claims 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662418859P | 2016-11-08 | 2016-11-08 | |
| US62/418,859 | 2016-11-08 | ||
| PCT/US2017/060383 WO2018089355A1 (en) | 2016-11-08 | 2017-11-07 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019537605A JP2019537605A (ja) | 2019-12-26 |
| JP2019537605A5 true JP2019537605A5 (https=) | 2020-12-17 |
| JP7264810B2 JP7264810B2 (ja) | 2023-04-25 |
Family
ID=60409434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523859A Active JP7264810B2 (ja) | 2016-11-08 | 2017-11-07 | アルファｖインテグリン阻害剤としてのシクロブタン－およびアゼチジン－含有の単環およびスピロ環式化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11014922B2 (https=) |
| EP (1) | EP3538526B1 (https=) |
| JP (1) | JP7264810B2 (https=) |
| KR (1) | KR102506324B1 (https=) |
| CN (1) | CN110167934B (https=) |
| AR (1) | AR110139A1 (https=) |
| AU (1) | AU2017359025A1 (https=) |
| BR (1) | BR112019009129A2 (https=) |
| CA (1) | CA3042710A1 (https=) |
| EA (1) | EA201991127A1 (https=) |
| ES (1) | ES2984394T3 (https=) |
| IL (1) | IL266470A (https=) |
| MA (1) | MA46744A (https=) |
| MX (1) | MX377359B (https=) |
| TW (1) | TW201819378A (https=) |
| WO (1) | WO2018089355A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| CN110177787A (zh) | 2016-12-29 | 2019-08-27 | 圣路易斯大学 | 整合素拮抗剂 |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MA47697A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'(alpha-v)(bêta-6) intégrine |
| TWI841573B (zh) * | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| FI3844162T3 (fi) | 2018-08-29 | 2025-03-27 | Morphic Therapeutic Inc | Alfa v beeta6 -integriinin estäjiä |
| WO2020047207A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| EP4086254B1 (en) | 2018-08-29 | 2024-12-18 | Morphic Therapeutic, Inc. | Integrin inhibitors |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| KR102659859B1 (ko) | 2018-10-30 | 2024-04-25 | 길리애드 사이언시즈, 인코포레이티드 | 알파4β7 인테그린의 억제를 위한 화합물 |
| CN112969700B (zh) | 2018-10-30 | 2024-08-20 | 吉利德科学公司 | 作为α4β7整合素抑制剂的咪唑并吡啶衍生物 |
| EP4541422A3 (en) | 2018-10-30 | 2025-06-25 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| KR102908219B1 (ko) | 2019-08-14 | 2026-01-08 | 길리애드 사이언시즈, 인코포레이티드 | 알파 4 베타 7 인테그린의 저해용 화합물 |
| WO2021175196A1 (zh) * | 2020-03-06 | 2021-09-10 | 清药同创(北京)药物研发中心有限公司 | 一种吡咯烷类整合素调节剂及其用途 |
| CA3176113A1 (en) * | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
| CN116134028A (zh) | 2020-07-07 | 2023-05-16 | 四川海思科制药有限公司 | 一种具有降解btk激酶的化合物及其制备方法和药学上的应用 |
| GB202010626D0 (en) * | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| WO2022022364A1 (zh) * | 2020-07-29 | 2022-02-03 | 清药同创(北京)药物研发中心有限公司 | 一种吡咯烷类整合素调节剂及其用途 |
| CR20230472A (es) * | 2021-03-10 | 2024-03-21 | Dice Molecules Sv Inc | Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos |
| IL308063A (en) * | 2021-04-30 | 2023-12-01 | Pliant Therapeutics Inc | Expanded dosage regimens for integrin inhibitors |
| US20250171417A1 (en) | 2021-08-11 | 2025-05-29 | Xizang Haisco Pharmaceutical Co., Ltd. | Heterocyclic derivative, and composition and pharmaceutical use thereof |
| EP4504187A4 (en) * | 2022-04-01 | 2026-04-08 | Praxis Prec Medicines Inc | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND THEIR METHODS OF USE |
| CN119300826A (zh) * | 2022-04-01 | 2025-01-10 | 普拉西斯精密医药公司 | 包含氮杂螺庚烷核的t型钙通道调节剂和其使用方法 |
| GB202301024D0 (en) | 2023-01-24 | 2023-03-08 | Univ Bradford | Compounds |
| CN117003681A (zh) * | 2023-07-04 | 2023-11-07 | 苏州汉德创宏生化科技有限公司 | 一种抑制剂类中间体及其合成方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| ZA972195B (en) * | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
| EP1049693A1 (en) | 1997-11-26 | 2000-11-08 | Du Pont Pharmaceuticals Company | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS |
| WO1999030709A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| WO2000009503A1 (en) | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| PT1187592E (pt) * | 1999-06-02 | 2007-10-19 | Merck & Co Inc | Antagonistas dos receptores de integrina alfa v |
| NZ539682A (en) | 2001-01-29 | 2006-03-31 | Dimensional Pharm Inc | Substituted indoles and their use as integrin antagonists |
| WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
| EP2049490A1 (en) | 2006-06-09 | 2009-04-22 | Astra Zeneca AB | N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| ITFI20100019A1 (it) | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| KR102647026B1 (ko) | 2015-02-19 | 2024-03-12 | 사이플루어 라이프 사이언시즈, 인크 | 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| WO2016172496A1 (en) * | 2015-04-23 | 2016-10-27 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and uses thereof |
| WO2018089353A1 (en) * | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | 3-substituted propionic acids as alpha v integrin inhibitors |
| SI3538528T1 (sl) * | 2016-11-08 | 2021-03-31 | Bristol-Myers Squibb Company | Pirol amidi kot alfa v integrin inhibitorji |
-
2017
- 2017-11-07 AU AU2017359025A patent/AU2017359025A1/en not_active Abandoned
- 2017-11-07 WO PCT/US2017/060383 patent/WO2018089355A1/en not_active Ceased
- 2017-11-07 MA MA046744A patent/MA46744A/fr unknown
- 2017-11-07 ES ES17801232T patent/ES2984394T3/es active Active
- 2017-11-07 EA EA201991127A patent/EA201991127A1/ru unknown
- 2017-11-07 JP JP2019523859A patent/JP7264810B2/ja active Active
- 2017-11-07 MX MX2019005306A patent/MX377359B/es active IP Right Grant
- 2017-11-07 CN CN201780082145.2A patent/CN110167934B/zh active Active
- 2017-11-07 KR KR1020197016079A patent/KR102506324B1/ko active Active
- 2017-11-07 CA CA3042710A patent/CA3042710A1/en not_active Abandoned
- 2017-11-07 US US16/347,849 patent/US11014922B2/en active Active
- 2017-11-07 EP EP17801232.4A patent/EP3538526B1/en active Active
- 2017-11-07 AR ARP170103089A patent/AR110139A1/es unknown
- 2017-11-07 BR BR112019009129A patent/BR112019009129A2/pt not_active Application Discontinuation
- 2017-11-07 TW TW106138359A patent/TW201819378A/zh unknown
-
2019
- 2019-05-06 IL IL266470A patent/IL266470A/en unknown
-
2021
- 2021-03-25 US US17/212,210 patent/US11639353B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019537605A5 (https=) | ||
| RU2012125372A (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
| RU2020108515A (ru) | Соединения и способы целевого расщепления андрогенного рецептора | |
| RU2454411C2 (ru) | Производные хинолина | |
| JP2016512203A5 (https=) | ||
| JP2021534124A5 (https=) | ||
| JP2004506718A5 (https=) | ||
| RU2315041C2 (ru) | Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения | |
| JP2020500182A5 (https=) | ||
| JP2005536475A5 (https=) | ||
| JP2017511794A5 (https=) | ||
| JP2013531070A5 (https=) | ||
| JP2016538313A5 (https=) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2007502264A5 (https=) | ||
| JP2013525458A5 (https=) | ||
| RU2014152276A (ru) | Замещенные пирролидины в качестве ингибиторов фактора xia для лечения тромбоэмболических заболеваний | |
| JP2007532651A5 (https=) | ||
| JP2007502806A5 (https=) | ||
| JP2010539110A5 (https=) | ||
| RU2019133530A (ru) | ПРОИЗВОДНЫЕ АМИДА В КАЧЕСТВЕ БЛОКАТОРОВ Nav1.7 И Nav1.8 | |
| JP2017535525A5 (https=) | ||
| RU2014103587A (ru) | Производные циклических аминов в качестве антагонистов рецептора ер4 | |
| JP2017509694A5 (https=) | ||
| RU2010129541A (ru) | Карбоксил- или гидроксилзамещенные производные бензимидазола |